ISSN: 1558-7673

Journal Home

Journal Guideline

Clinical Genitourinary Cancer Q1 Unclaimed

Elsevier Inc. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Clinical Genitourinary Cancer is a journal indexed in SJR in Oncology and Urology with an H index of 57. It has a price of 3047 €. It has an SJR impact factor of 1,056 and it has a best quartile of Q1. It has an SJR impact factor of 1,056.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Urology (Q1) Oncology (Q2)

Price

3047 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,056

SJR Impact factor

57

H Index

159

Total Docs (Last Year)

448

Total Docs (3 years)

4887

Total Refs

1127

Total Cites (3 years)

433

Citable Docs (3 years)

2.39

Cites/Doc (2 years)

30.74

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Molecular Cancer Q1
Journal of Thoracic Oncology Q1
JAMA oncology Q1
Cancer Discovery Q1
Journal of Hematology and Oncology Q1

Compare this journals

Aims and Scope

Best articles by citations

Could Bladder Multiparametric MRI Be Introduced in Routine Clinical Practice? Role of the New VI-RADS Score: Results From a Prospective Study

Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma

Highlights from the International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications Philadelphia, PA, November 2005 ECCO 13-The EuropeanCancer Conference Paris, France, October 30 - November 3, 200

Improving Outcomes With Recent Advances in Chemotherapy for Castrate-Resistant Prostate Cancer

Differing Risk of Cancer Death Among Patients With Pathologic T3a Renal Cell Carcinoma: Identification of Risk Categories According to Fat Infiltration and Renal Vein Thrombosis

Trends in Renal Function After Radical Cystectomy and Ileal Conduit Diversion: New Insights Regarding Estimated Glomerular Filtration Rate Variations

Selected Clinical Trials in Genitourinary Cancer

Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center

Highlights from: The 2008 Genitourinary Cancers Symposium; February 14-16, 2008; San Francisco, CA

Long-Term Administration of Docetaxel Over 70 Cycles for Castration-Resistant Prostate Cancer

Highlights from: The 2008 Meeting of the American Society of Clinical Oncology; May 30-June 3, 2008; Chicago, IL

Highlights from: The Third International Congress on Kidney and Bladder Cancer; Orlando, FL; August 3-6, 2006

SHOW MORE ARTICLES

Clinical Outcomes of Patients With Histologic Variants of Urothelial Carcinoma Treated With Selective Tetramodal Bladder-preservation Therapy Incorporating Consolidative Partial Cystectomy

Selected Clinical Trials in Prostate and Renal Cancer

Prostate Cancer in the Arab World: A View From the Inside

Prostate Cancer Incidence and Mortality in Relationship to Family History of Prostate Cancer; Findings From The PLCO Trial

Retroperitoneal Robot-Assisted Versus Open Partial Nephrectomy for cT1 Renal Tumors: A Matched-Pair Comparison of Perioperative and Early Oncological Outcomes

Delayed Antiandrogen Withdrawal Syndrome After Discontinuation of Bicalutamide

Positive Surgical Margins Predict Progression-free Survival After Nephron-sparing Surgery for Renal Cell Carcinoma: Results From a Single Center Cohort of 459 Cases With a Minimum Follow-up of 5 Years

Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer

Hyperlipidemia and Hypothyroidism Among Metastatic Renal Cell Carcinoma Patients Taking Sunitinib Malate. Related or Unrelated Adverse Events?

Medicaid Expansion Did not Improve Time to Treatment for Young Patients With Metastatic Renal Cell Carcinoma

A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer

Safety of I.V. Nonnitrogen Bisphosphonates on the Occurrence of Osteonecrosis of the Jaw: Long-Term Follow-Up on Prostate Cancer Patients